Heparin is often used to prevent or treat thromboembolism in cancer patients. Clinical and experimental evidence suggest that heparin also has anti-cancer activities. Experimental evidence consistently supports the ability of heparin to attenuate metastasis. The potential anti-metastatic effects of heparin include the inhibition of cell-cell interactions or heparanase and modulation of growth factors and anticoagulant activity. Heparin inhibits selectin-mediated interactions of tumor cells with leukocytes, platelets and endothelial cells, which are likely to mediate the initial steps of hematogenous metastasis. Prospective clinical trials can be designed based on the insights obtained from experimental studies. 
I Cancer-Thrombosis-Heparin
Thromboembolic events are frequent complications in cancer patients and represent a major reason of morbidity and mortality (1) (2) (3) . The hypercoagulable state often observed in cancer patients is either activated by the tumor itself or due to anticancer treatment-related factors. Several molecular pathways leading to this procoagulant state were identified and are thoroughly reviewed elsewhere (e.g. see reviews 4, 5), Tissue factor (TF), a main inducer of the coagulation cascade, is upregulated either by oncogenic activation or the loss of tumor suppressors in tumor cells and in activated endothelial cells within the tumor stroma (6, 7) . Recently, a novel mechanism was described, which links the MET oncogene to an increased expression of COX-2 and PAI-1, thereby inducing a procoagulant state (8) . PAI-1 and TF are also upregulated in hypoxic areas of tumors, thus suggesting a connection between the HIF pathway and hemostasis (9) . Moreover, mucins of adenocarcinomas were shown to activate the hemostatic system via selectinmediated interactions between leukocytes and platelets (10) . Standard anticoagulant therapy of cancer patients which experience thromboembolism or receive chemotherapy are mostly treated with heparin or oral vitamin K antagonist. Lowmolecular weight heparin therapy was shown to be associated with an improved survival of cancer patients (1, (11) (12) (13) (14) .
Heparin is a natural glycosaminoglycan molecule and consists of N-and O-sulfated alternating galactosamine/glucosamine and glucoronic/iudoronic acid carbohydrate moieties (15) . Unfractionated heparin (UFH) is isolated from porcine intestine and represents a very heterogeneous mixture of polymers containing of about 200-300 monosaccharides. Depolymerisation and fractionation of UFH results in the generation of low molecular weight heparin (LMWH) with more constrained biological activity (15) . Importantly, the characterization of the antithrombin binding pentasaccharide sequence led to the identification of the heparin active site (15) .
Many activities of heparin are known to affect the biology of tumor cells, but only a few of them are relevant in vivo (16) (17) (18) (19) . In this review, we will discuss the in vivo activities of heparin on tumor progression, with a special emphasis on the inhibition of selectin-mediated cell-cell interactions and heparanase activity during hematogenous dissemination.
II Heparin as cancer treatment: Impact on patient survival
Heparin is commonly used for the prevention or treatment of venous thromboembolism. Its effect on tumor progression in cancer patients, however, remains controversial. The positive effect of heparin on survival of cancer patients was evaluated in several clinical studies and excellently reviewed elsewhere (e.g. see reviews 13, 14) .
Several prospective, randomized and placebo-controlled studies were specifically planned to analyze heparin as an anti-cancer drug. One such multicenter trial involving 138 patients with small lung cancer demonstrated a significant reduction of mortality and increased complete response rate in the group treated with UFH subcutaneously over a period of 5 weeks (20) . In another study by Altinbas and colleagues, small lung cancer patients (n=84) were treated with dalteparin or placebo in parallel to normal chemotherapy regimens (21) . The group treated with chemotherapy and dalteparin had a significantly prolonged median survival.
However, no significant differences were observed in advanced cancer patients treated with nadroparin for 2 years (n=138), (22) . Although a trend towards an increased survival in the nadroparin group could be determined. In the FAMOUS study of Kakkar and associates 374 patients with advanced malignancies (Stage III, IV) were treated with dalteparin over a period of 1 year. After 3 years, the dalteparin group showed a higher survival rate, albeit not significantly (p=0.19). Interestingly, a not a priori defined subgroup analysis of patients with an initial better prognosis resulted in a significantly improved survival of the dalteparin treated patients (23) .
The MALT study was conducted to test the effect of a 6 week treatment with nadroparin on the survival of patients with advanced cancer of various origins (n=302) (24) . Nadroparin treatment led to an improvement of survival by 12% after one year and 10% after two years (p=0.021). These subgroup analyses of patients with better prognosis in the FAMOUS and the MALT studies make heparin an interesting candidate to be tested during early stages of cancer. Meta-analysis of all patients, including those in above mentioned studies, demonstrated a significant improvement of the survival in the LMWH treated group (13, 25) .
The CLOT study was designed to compare the effect of LMWH or oral anticoagulation on the prevention of recurrent venous thromboembolism in cancer patients with acute venous thrombosis or pulmonary embolism (26, 27). A treatment with nadroparin for six months was significantly more effective than oral anticoagulation (26). A posthoc analysis in a subgroup of patients without metastases resulted in the detection of an increased survival in the dalteparin treated arm of the study (27) . In contrast to heparin treatment, other studies using coumarin derivatives in cancer patients failed to show any decrease in mortality (13, 14) .
Based on these promising results together with observations from animal models, heparin seems to directly affect cancer progression. Meanwhile, animal models help to study and to validate the activity of heparin during metastasis.
III Heparin attenuates metastasis in mouse models
Several animal models were used to test heparins as a potential anti-cancer and thereby makes it possible to narrow down the potential mechanism. However, several aspects of metastasis including lymphatic dissemination, local tumor invasion and intravasation can be better examined in spontaneous metastasis models. For more than 40 years, UFH was repeatedly shown to reduce experimental and spontaneous metastasis in rodents (for review see (17, 19) . Because UFH consists of highly heterogeneous polysaccharide chains with a wide variety of biological activities, the determination of the molecular mechanisms responsible for the antimetastatic effect was difficult (17, 28) . A first hint was derived from spontaneous metastasis models that showed that the primary tumor size was only minimally affected, while metastasis was clearly reduced (17, 29) . This observation led to the conclusion that metastasis rather than tumor growth is inhibited by heparin treatment.
Many mouse studies analyzing the effect of heparin on metastasis have been reported (for review see (17, 19) . In these studies, different tumor cells, including human and mouse carcinoma and melanoma cells were used, and a variety of heparins, including UFH, various low molecular weight heparins (LMWHs) and chemically modified heparins were evaluated. While the method of application as well as the time period of heparin treatment varied among these studies, the antimetastatic effect of heparin treatment was observed mostly in situations when heparin was applied when tumor cells were still in circulation. In general, a bolus injection of heparin or LMWH prior to tumor cell application was shown to attenuate metastasis of colon, lung and breast carcinoma, as well as melanoma (28, (30) (31) (32) (33) (34) . In all these studies the applied concentration of heparins exceeded the therapeutical doses. Nevertheless, recent studies have confirmed that also clinically relevant doses of UFH and LMWHs efficiently attenuated experimental metastasis (35, 36).
IV "Anti-cancer" activity of heparin
Heparin is a complex mixture of glycosaminoglycans containing a variety of biological activities. Although clinical preparations of heparin are enriched for its ability to inhibit coagulation, heparin also contains activity to: block P-and L-selectins, alter integrin binding, affect activity of growth factors and cytokines, inhibit heparanase and angiogenesis, modulate the activity of proteases and thereby the components of extracellular matrix (15, 17, 18, (37) (38) (39) (40) . While any of these activities could potentially affect cancer progression, all the experimental evidence strongly suggests that 
V Anticoagulant activity of heparin and metastasis
The use of heparin in cancer management indicated effects seemingly unrelated to its anticoagulant properties (37, 42, 43). Heparin effect on metastasis was also demonstrated in animal models and confirmed to be additional to its anticoagulant activity (17, 44) . In addition the capacity of heparin to release TFPI from the vasculature was shown to affect metastasis (41). Non-anticoagulant heparin derivatives were shown to attenuate experimental metastasis, thus confirming that the effect on the coagulation system is rather limited with respect to the other antimetastatic properties of heparin (29, 30, 34, 45-48). Experimental studies have shown that the use of an anti-thrombin inhibitor, hirudin, reduces metastasis (49, 50).
However, in both these studies the amount used of hirudin resulted in an excessive anticoagulation, which is not compatible with clinical applications. Finally, the pentasaccharide fondaparinux, which specifically inhibits antithrombin did not reduce metastasis in mice at clinically tolerable levels (35, 36). Platelet aggregates were detected also by tumor cells not carrying P-selectin ligands, thus it is possible that P-selectin mediates also aggregations of platelets (50) .
VI Heparin inhibits heparanase
In addition, the endothelial P-selectin expression was demonstrated to contribute to metastasis (33). Lethal irradiation of P-selectin deficient mice followed by bone and also since heparin showed no effect in P-selectin deficient mice, early heparin treatment likely affects primarily P-selectin mediated interactions during early steps of metastasis.
The additional reduction of metastasis achieved by early heparin treatment in the absence of L-selectin indicates that the L-selectin-dependent involvement of leukocytes is an event subsequent to the initial P-selectin-mediated platelet aggregation. This is in agreement with the observation that a temporal inhibition of L-selectin several hours after the tumor cell injection resulted in attenuation of metastasis comparable to the one seen in L-selectin deficient mice (65) . Similarly, heparin injection several hours (6-12 h) after the tumor cell injection -"late heparin"
led to an attenuation of metastasis in P-selectin deficient mice, but had no effect on metastasis in L-selectin deficient mice (65) . Finally, the evidence that heparin affects P-and L-selectin and thereby attenuates metastasis was obtained in mice deficient both in P-and L-selectin (PL-sel-/-). Treatment of PL-sel-/-mice either with "early" or "late" heparin had no effect on metastasis observed in these mice (32). Interestingly, Several prospective clinical trials indicate that LMWH affects cancer progression, and this effect cannot be solely ascribed to prevention of thrombo-embolism (23, 24, 27) .
Recently a rationale for a clinical study on heparin treatment of cancer has been 
